Skip to main content
Erschienen in: PharmacoEconomics 12/2012

01.12.2012 | Original Research Article

Impact of Transformation of Negative Values and Regression Models on Differences Between the UK and US EQ-5D Time Trade-Off Value Sets

verfasst von: Ms Liv Ariane Augestad, Kim Rand-Hendriksen, Ivar Sønbø Kristiansen, Knut Stavem

Erschienen in: PharmacoEconomics | Ausgabe 12/2012

Einloggen, um Zugang zu erhalten

Abstract

Background

National EQ-5D value sets are developed because preferences for health may vary in different populations. UK values are lower than US values for most of the 243 possible EQ-5D health states. Although similar protocols were used for data collection, analytic choices regarding how to model values from the collected data may also influence national value sets. Participants in the UK and US studies assessed the same subset of 42 EQ-5D health states using the time trade-off (TTO) method. However, different methods were used to transform negative values to a range bounded by 0 and −1, and values for all 243 health states were estimated using two different regression models. The transformation of negative values is inconsistent with expected utility theory, and the choice of which transformation method to use lacks a theoretical foundation.

Objectives

Our objectives were to assess how much of the observed difference between the UK and US EQ-5D value sets may be explained by the choice of transformation method for negative values relative to the choice of regression model and the differences between elicited TTO values in the respective national studies (datasets).

Methods

We applied both transformation methods and both regression models to each of the two datasets, resulting in eight comparable value sets. We arranged these value sets in pairs in which one source of difference (transformation method, regression model or dataset) was varied. For each of these paired value sets, we calculated the mean difference between the two matching values for each of the 243 health states. Finally, we calculated the mean utility gain for all possible transitions between pairs of EQ-5D health states within each value set and used the difference in transition scores as a measure of impact from changing transformation method, regression model or dataset.

Results

The mean absolute difference in values was 1.5 times larger when changing the transformation method than when using different datasets. The choice of transformation method had a 3.2 times larger effect on the mean health gain (transition score) than the choice of dataset. The mean health gain in the UK value set was 0.09 higher than in the US value set. Using the UK transformation method on the US dataset reduced this absolute difference to 0.02. The choice of regression model had little overall impact on the differences between the value sets.

Conclusions

Most of the observed differences between the UK and US value sets were caused by the use of different transformation methods for negative values, rather than differences between the two study populations as reflected in the datasets. Changing the regression model had little impact on the differences between the value sets.
Literatur
1.
Zurück zum Zitat Szende A, Oppe M, Devlin NJ, et al., editors. EQ-5D value sets: inventory, comparative review and user guide [EuroQol Group monographs vol. 2]. Dordrecht: Springer, 2006 Szende A, Oppe M, Devlin NJ, et al., editors. EQ-5D value sets: inventory, comparative review and user guide [EuroQol Group monographs vol. 2]. Dordrecht: Springer, 2006
2.
Zurück zum Zitat Drummond MF. Methods for the economic evaluation of health care programmes. 3rd rev. ed. Oxford: Oxford University Press, 2005 Drummond MF. Methods for the economic evaluation of health care programmes. 3rd rev. ed. Oxford: Oxford University Press, 2005
3.
Zurück zum Zitat Dolan P, Gudex C, Kind P, et al. The time trade-off method: results from a general population study. Health Econ 1996 Mar; 5(2): 141–54CrossRef Dolan P, Gudex C, Kind P, et al. The time trade-off method: results from a general population study. Health Econ 1996 Mar; 5(2): 141–54CrossRef
4.
Zurück zum Zitat Johnson JA, Luo N, Shaw JW, et al. Valuations of EQ-5D health states: are the United States and United Kingdom different? Med Care 2005 Mar; 43(3): 221–8CrossRef Johnson JA, Luo N, Shaw JW, et al. Valuations of EQ-5D health states: are the United States and United Kingdom different? Med Care 2005 Mar; 43(3): 221–8CrossRef
5.
Zurück zum Zitat Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005 Mar; 43(3): 203–20CrossRef Shaw JW, Johnson JA, Coons SJ. US valuation of the EQ-5D health states: development and testing of the D1 valuation model. Med Care 2005 Mar; 43(3): 203–20CrossRef
6.
Zurück zum Zitat Dolan P. Modeling valuations for EuroQol health states. Med Care 1997 Nov; 35(11): 1095–108CrossRef Dolan P. Modeling valuations for EuroQol health states. Med Care 1997 Nov; 35(11): 1095–108CrossRef
7.
Zurück zum Zitat Patrick DL, Starks HE, Cain KC, et al. Measuring preferences for health states worse than death. Med Decis Making 1994 Feb; 14(1): 9–18CrossRef Patrick DL, Starks HE, Cain KC, et al. Measuring preferences for health states worse than death. Med Decis Making 1994 Feb; 14(1): 9–18CrossRef
8.
Zurück zum Zitat Tilling C, Devlin N, Tsuchiya A, et al. Protocols for time tradeoff valuations of health states worse than dead: a literature review. Med Decis Making 2010; 30(5): 610–9CrossRef Tilling C, Devlin N, Tsuchiya A, et al. Protocols for time tradeoff valuations of health states worse than dead: a literature review. Med Decis Making 2010; 30(5): 610–9CrossRef
9.
Zurück zum Zitat Lamers LM. The transformation of utilities for health states worse than death: consequences for the estimation of EQ-5D value sets. Med Care 2007 Mar; 45(3): 238–44CrossRef Lamers LM. The transformation of utilities for health states worse than death: consequences for the estimation of EQ-5D value sets. Med Care 2007 Mar; 45(3): 238–44CrossRef
10.
Zurück zum Zitat Noyes K, Dick AW, Holloway RG. The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation. Med Decis Making 2007; 27(3): 327–34CrossRef Noyes K, Dick AW, Holloway RG. The implications of using US-specific EQ-5D preference weights for cost-effectiveness evaluation. Med Decis Making 2007; 27(3): 327–34CrossRef
11.
Zurück zum Zitat Nan L, Johnson JA, Shaw JW, et al. A comparison of EQ-5D index scores derived from the US and UK population-based scoring functions. Med Decis Making 2007; 27(3): 321–6CrossRef Nan L, Johnson JA, Shaw JW, et al. A comparison of EQ-5D index scores derived from the US and UK population-based scoring functions. Med Decis Making 2007; 27(3): 321–6CrossRef
12.
Zurück zum Zitat Noyes K, Dick AW, Holloway RG. Pramipexole v. levodopa as initial treatment for Parkinson’s disease: a randomized clinical-economic trial. Med Decis Making 2004; 24(5): 472–85CrossRef Noyes K, Dick AW, Holloway RG. Pramipexole v. levodopa as initial treatment for Parkinson’s disease: a randomized clinical-economic trial. Med Decis Making 2004; 24(5): 472–85CrossRef
13.
Zurück zum Zitat Norman R, Cronin P, Viney R, et al. International comparisons in valuing EQ-5D health states: a review and analysis. Value Health 2009; 12(8): 1194–200CrossRef Norman R, Cronin P, Viney R, et al. International comparisons in valuing EQ-5D health states: a review and analysis. Value Health 2009; 12(8): 1194–200CrossRef
14.
Zurück zum Zitat Knies S, Evers SM, Candel MJ, et al. Utilities of the EQ-5D: transferable or not? Pharmacoeconomics 2009; 27(9): 767–79CrossRef Knies S, Evers SM, Candel MJ, et al. Utilities of the EQ-5D: transferable or not? Pharmacoeconomics 2009; 27(9): 767–79CrossRef
15.
Zurück zum Zitat Fryback DG. A US valuation of the EQ-5D. Med Care 2005 Mar; 43(3): 199–200CrossRef Fryback DG. A US valuation of the EQ-5D. Med Care 2005 Mar; 43(3): 199–200CrossRef
16.
Zurück zum Zitat Devlin NJ, Tsuchiya A, Buckingham K, et al. A uniform time trade off method for states better and worse than dead: feasibility study of the “lead time” approach. Health Econ 2011; 20(3): 348–61CrossRef Devlin NJ, Tsuchiya A, Buckingham K, et al. A uniform time trade off method for states better and worse than dead: feasibility study of the “lead time” approach. Health Econ 2011; 20(3): 348–61CrossRef
17.
Zurück zum Zitat Craig BM, Busschbach JJ. The episodic random utility model unifies time trade-off and discrete choice approaches in health state valuation. Popul Health Metr 2009 Jan; 7: 3CrossRef Craig BM, Busschbach JJ. The episodic random utility model unifies time trade-off and discrete choice approaches in health state valuation. Popul Health Metr 2009 Jan; 7: 3CrossRef
18.
Zurück zum Zitat Dolan P, Roberts J. Modelling valuations for EQ-5D health states: an alternative model using differences in valuations. Med Care 2002; 40(5): 442–6CrossRef Dolan P, Roberts J. Modelling valuations for EQ-5D health states: an alternative model using differences in valuations. Med Care 2002; 40(5): 442–6CrossRef
20.
Zurück zum Zitat Robinson A, Spencer A. Exploring challenges to TTO utilities: valuing states worse than dead. Health Econ 2006 Apr; 15(4): 393–402CrossRef Robinson A, Spencer A. Exploring challenges to TTO utilities: valuing states worse than dead. Health Econ 2006 Apr; 15(4): 393–402CrossRef
21.
Zurück zum Zitat Shaw JW, Pickard AS, Yu S, et al. A median model for predicting United States population-based EQ-5D health state preferences. Value Health 2010; 13(2): 278–88CrossRef Shaw JW, Pickard AS, Yu S, et al. A median model for predicting United States population-based EQ-5D health state preferences. Value Health 2010; 13(2): 278–88CrossRef
Metadaten
Titel
Impact of Transformation of Negative Values and Regression Models on Differences Between the UK and US EQ-5D Time Trade-Off Value Sets
verfasst von
Ms Liv Ariane Augestad
Kim Rand-Hendriksen
Ivar Sønbø Kristiansen
Knut Stavem
Publikationsdatum
01.12.2012
Verlag
Springer International Publishing
Erschienen in
PharmacoEconomics / Ausgabe 12/2012
Print ISSN: 1170-7690
Elektronische ISSN: 1179-2027
DOI
https://doi.org/10.2165/11595420-000000000-00000

Weitere Artikel der Ausgabe 12/2012

PharmacoEconomics 12/2012 Zur Ausgabe

Original Research Article

Chemotherapy Administration

Acknowledgments

Acknowledgement